Compare Amphastar Pharmaceuticals Inc (AMPH) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

AVDV trades at $104.2, up 1.04% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international small-cap value stocks from developed markets, offering diversification and a modest dividend, with a $1.39 dividend scheduled for June 2026. Recent news highlights its 35% gains in 2026, outperforming the S&P 500 by 5.7%, though some analysts express caution about cyclical reliance.

The outlook is mixed: strong recent performance and institutional interest support upside, but bearish technicals and concerns over structural alpha pose risks. Investors should weigh the ETF's value approach against potential volatility from international markets and sector cycles.